[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:t-cell-histiocyte-rich-large-b-cell-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":74,"states":85},"T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma",10,7,[8,16,22,29,36,42,48,54,61,68],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:16:17.877565Z","2026-06-16T05:54:07.922088Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05934448","Pembro Plus CAR T-cell Therapy in R\u002FR in PMBCL",[12],"2026-08-26T02:16:29.226604Z","2026-05-05T02:43:27.574296Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07123454","A Phase I\u002FII Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[26],"Phase 1\u002FPhase 2","2026-08-26T02:19:29.119921Z","2026-07-05T05:32:16.737268Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[33],"Phase 1","2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.261789Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06811272","Outpatient Epcoritamab as 2L in NTE R\u002FR DLBCL",[12],"2026-08-26T02:19:08.862440Z","2026-05-05T02:43:26.689921Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",{"nct_id":55,"title":56,"phases":57,"status":58,"updated_at":59,"content_modified":60},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.200627Z",{"nct_id":62,"title":63,"phases":64,"status":65,"updated_at":66,"content_modified":67},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[33],"ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:28.883413Z",{"nct_id":69,"title":70,"phases":71,"status":65,"updated_at":72,"content_modified":73},"NCT05821088","Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed\u002F Refractory Large B-Cell Lymphoma",[12],"2026-08-03T03:19:35.241322Z","2026-05-05T02:43:26.683044Z",[75,79,82],{"biomarker":76,"count":77,"slug":78},"BCL2 Gene",3,"bcl2-gene",{"biomarker":80,"count":77,"slug":81},"BCL6 Gene","bcl6-gene",{"biomarker":83,"count":77,"slug":84},"MYC Gene","myc-gene",[86,89,92,95,98],{"state":87,"count":77,"slug":88},"California","california",{"state":90,"count":77,"slug":91},"Minnesota","minnesota",{"state":93,"count":77,"slug":94},"New York","new-york",{"state":96,"count":77,"slug":97},"Ohio","ohio",{"state":99,"count":77,"slug":100},"Washington","washington"]